

This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|---------------|---|--|---|---|
| Cancer | | | | |
| Leukemia | Myeloid or mixed-lineage leukemia-ENL fusion protein (MLL-ENL fusion protein) | <p>Studies <i>in vitro</i> and in mice suggest that blocking expression of the oncogenic MLL-ENL fusion protein may help treat certain leukemias. Mice with transplanted myeloid cells carrying a conditionally expressed <i>Mll-Enl</i> transgene developed leukemias with a variety of chromosomal mutations.</p> <p>Inhibition of MLL-ENL expression in those mice prevented further leukemic splenocyte proliferation and eliminated leukemic cells from the peripheral blood. Next steps should include determining the therapeutic potential of interfering with oncogenic pathways downstream of MLL-ENL.</p> <p>SciBX 2(1); doi:10.1038/scibx.2009.11 Published online Jan. 8, 2009</p> | Patent and licensing status unavailable | <p>Horton, S. <i>et al. Blood</i>; published online Nov. 24, 2008; doi:10.1182/blood-2008-07-170480</p> <p>Contact: Owen Williams, University College London Institute of Child Health, London, U.K. e-mail: owen.williams@ich.ucl.ac.uk</p> |